7 Results for "

WIN site

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "WIN site" in MCE Product Catalog:

  • Targets Recommended:
5
5 Cited Publications
Cat. No.: HY-111753
CAS No.: 2407457-36-5
Purity:  98.13%
Target:  

WDR5 Apoptosis

Research Areas:  

Cancer

WDR5-IN-4 (Compound C6) is a WIN site inhibitor of chromatin-associated WD repeat domain 5 protein (WDR5), Kd The value is 0.1 nM. WDR5-IN-4 is able to displace WDR5 from chromatin and reduce the expression of related genes, causing translation inhibition and nucleolar stress. Has anti-cancer effects .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-111753A
CAS No.: 2749300-35-2
Purity:  99.87%
Target:  

WDR5 Apoptosis

Research Areas:  

Cancer

WDR5-IN-4 TFA (Compound C6) is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 TFA displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity .
loading...
    loading...
Cat. No.: HY-154949
CAS No.: 326901-92-2
Purity:  99.83%
Target:  

WDR5

Research Areas:  

Cancer

WDR5-IN-6 is a WDR5 inhibitor, targeting to WBM site. WDR5-IN-6 inhibits cell proliferation of neuroblastoma cell lines with potent anti-tumor activity. WDR5-IN-6 shows high synergy with OICR-9429 (HY-16993), a WDR5 inhibitor targeting to WIN site. WDR5-IN-6 can be used for reasearch in neuroblastoma .
loading...
    loading...
Cat. No.: HY-150654
CAS No.: 2417012-26-9
Purity:  99.56%
Target:  

WDR5

Research Areas:  

Cancer

WDR5-IN-5 is an orally active and selective inhibitor of WIN site of WD repeat domain 5 (WDR5). WDR5-IN-5 exhibits anti-proliferative activity towards cancer cells and good pharmacokinetics profile in mice. WDR5-IN-5 shows high affinity to WDR5 and the binding affinity Ki value <0.02 nM .
loading...
    loading...
Cat. No.: HY-148817
CAS No.: 824960-50-1
Purity:  97.02%
Target:  

WDR5

Research Areas:  

Cancer

WDR5-0102 is an inhibitor of WDR5. WDR5-0102 specifically targets the WIN site of WDR5, disrupts the WDR5-MLL1 interaction, and reduces the histone methyltransferase activity of MLL1. WDR5-0102 exerts dose-dependent toxicity on MDSC-like cells and reduces their osteopontin levels, while showing extremely low cytotoxicity to pancreatic cancer cells. WDR5-0102 can be used in the research of related diseases such as acute myeloid leukemia, lymphoid leukemia, biphenotypic leukemia and pancreatic cancer .
loading...
    loading...
Cat. No.: HY-175754
Target:  

WDR5

Research Areas:  

Cancer

C3TD078 is a WDR5 WIN site inhibitor with a Ki of 0.03  nM. C3TD078 has potent antiproliferative activity and reduces the stem-cell frequency of cancer stem cells (CSCs). C3TD078 can be used for glioblastoma (GBM) research .
loading...
    loading...
Cat. No.: HY-111753AR
CAS No.: 2749300-35-2
Research Areas:  

Cancer

WDR5-IN-4 TFA (Standard) is the analytical standard of WDR5-IN-4 (TFA) (HY-111753A). This product is intended for research and analytical applications. WDR5-IN-4 TFA (Compound C6) is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. WDR5-IN-4 TFA displaces WDR5 from chromatin and decreases the expression of associated genes, causing translational inhibition, nucleolar stress. Anti-cancer activity .
loading...
    loading...